Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells by Sung, Julia A.M. et al.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
4 0 7 7jci.org   Volume 125   Number 11   November 2015
Introduction
The inability of antiretroviral therapy (ART) to eradicate HIV was 
first suggested by the demonstration of latent infection of resting 
CD4+ T cells (1) and then by the recovery of rare, integrated, rep-
lication-competent HIV from the resting CD4+ memory T cells of 
patients receiving potent ART (2–4). Current ART cannot eradicate 
HIV infection because these long-lived CD4+ T cells remain persis-
tently infected and unrecognized by the immune system, with min-
imal expression of HIV genes or proteins (1, 5, 6). The persistence of 
quiescent HIV infection, primarily within central memory T cells, is 
a major obstacle to eradication of HIV infection (2–4, 7–9).
Viral persistence is also manifest in a substantial proportion 
of treated patients by very low levels of detectable viral RNA (10, 
11) that represents expression of viral particles without effective 
rounds of new replication and does not appear to lead to drug 
resistance or failure of therapy (12, 13). However, persistent vire-
mia demonstrates an inability of the immune response to recog-
nize and clear HIV-1–infected cells.
Chronically infected individuals generally have rapid viral 
rebound when ART is withdrawn (14–16). This observation has 
suggested that the immune system in patients cannot control 
viremia, unless bolstered by a further intervention. Therapeu-
tic immunization, even in individuals who initiated ART when 
CD4+ and CD8+ cellular immune responses remain relatively 
preserved, has thus far been unsuccessful in inducing enhanced 
anti-HIV immunity that can restrict viremia in the absence of 
ART (17). Therefore, eliminating the latent pool of HIV-infected 
cells that persist despite ART, as well as the unknown cells that 
are the source of low-level viremia found in most patients despite 
ART, requires new and innovative strategies. One initial step, the 
Enhancement of HIV-specific immunity is likely required to eliminate latent HIV infection. Here, we have developed an 
immunotherapeutic modality aimed to improve T cell–mediated clearance of HIV-1–infected cells. Specifically, we employed 
Dual-Affinity Re-Targeting (DART) proteins, which are bispecific, antibody-based molecules that can bind 2 distinct cell-
surface molecules simultaneously. We designed DARTs with a monovalent HIV-1 envelope-binding (Env-binding) arm that 
was derived from broadly binding, antibody-dependent cellular cytotoxicity–mediating antibodies known to bind to HIV-
infected target cells coupled to a monovalent CD3 binding arm designed to engage cytolytic effector T cells (referred to as 
HIVxCD3 DARTs). Thus, these DARTs redirected polyclonal T cells to specifically engage with and kill Env-expressing cells, 
including CD4+ T cells infected with different HIV-1 subtypes, thereby obviating the requirement for HIV-specific immunity. 
Using lymphocytes from patients on suppressive antiretroviral therapy (ART), we demonstrated that DARTs mediate CD8+ T 
cell clearance of CD4+ T cells that are superinfected with the HIV-1 strain JR-CSF or infected with autologous reservoir viruses 
isolated from HIV-infected–patient resting CD4+ T cells. Moreover, DARTs mediated CD8+ T cell clearance of HIV from resting 
CD4+ T cell cultures following induction of latent virus expression. Combined with HIV latency reversing agents, HIVxCD3 
DARTs have the potential to be effective immunotherapeutic agents to clear latent HIV-1 reservoirs in HIV-infected individuals. 
Dual-Affinity Re-Targeting proteins direct  
T cell–mediated cytolysis of latently HIV-infected cells
Julia A.M. Sung,1 Joy Pickeral,2 Liqin Liu,3 Sherry A. Stanfield-Oakley,2 Chia-Ying Kao Lam,3 Carolina Garrido,1 Justin Pollara,2  
Celia LaBranche,2 Mattia Bonsignori,4,5 M. Anthony Moody,5,6 Yinhua Yang,3 Robert Parks,5 Nancie Archin,1 Brigitte Allard,1  
Jennifer Kirchherr,1 JoAnn D. Kuruc,1 Cynthia L. Gay,1 Myron S. Cohen,1 Christina Ochsenbauer,7 Kelly Soderberg,5 Hua-Xin Liao,4,5 
David Montefiori,2,5 Paul Moore,3 Syd Johnson,3 Scott Koenig,3 Barton F. Haynes,4,5 Jeffrey L. Nordstrom,3  
David M. Margolis,1 and Guido Ferrari2,5
1Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2Department of Surgery, Duke University, Durham, North Carolina, USA. 3MacroGenics, Inc., Rockville, 
Maryland, USA. 4Department of Medicine, Duke University, Durham, North Carolina, USA. 5Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA. 6Department of 
Pediatrics, Duke University, Durham, North Carolina, USA. 7Division of Hematology and Oncology, University of Alabama-Birmingham, Birmingham, Alabama, USA.
Authorship note: Julia A. Sung, Joy Pickeral, and Liqin Liu contributed equally to this work.
Note regarding evaluation of this manuscript: Manuscripts authored by scientists 
associated with Duke University, The University of North Carolina at Chapel Hill, 
Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by 
members of the editorial board but rather by the science editors, who consult with 
selected external editors and reviewers.
Conflict of interest: Mattia Bonsignori, M. Anthony Moody, Hua-Xin Liao, Barton F. 
Haynes, and Guido Ferrari have filed patent applications on the 2 mAbs described and 
related antigens used in this study. David M. Margolis has personal equity investments 
unrelated to the submitted manuscript in Gilead Sciences. Liqin Liu, Chia-Ying Kao Lam, 
Paul Moore, Syd Johnson, Jeffrey L. Nordstrom, and Scott Koenig are employees of Macro-
Genics, Inc., and receive salaries and stock options as compensation for their employ-
ment. Chia-Ying Kao Lam, Syd Johnson, and Scott Koenig have filed for intellectual patent 
rights on aspects of the current research. Scott Koenig has personal equity investments in 
health care companies unrelated to the submitted manuscript, including Abbvie, Abbott, 
Alexion, Biogen, Celldex, GlaxoSmithKline, Johnson & Johnson, Monsanto, Merck, Pfizer, 
Seattle Genetics, Sunesis, and Zafgen.
Submitted: April 13, 2015; Accepted: August 17, 2015.
Reference information: J Clin Invest. 2015;125(11):4077–4090. doi:10.1172/JCI82314.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
4 0 7 8 jci.org   Volume 125   Number 11   November 2015
proteins (BiTEs), have been characterized and developed largely 
for use in oncology (31–34). They are dependent on the engage-
ment of both of the binding arms to activate and redirect the cyto-
lytic activity of polyclonal T cells, in a major histocompatibility 
complex–independent (MHC-independent) manner, against the 
antigen-expressing target cells (31–34). This class of bispecific 
molecules is effective in vivo at doses many-fold lower than those 
typically employed for mAbs (33, 34) and has been shown to be 
clinically potent and efficacious with acceptable safety, as evi-
denced by the approval of blinatumomab, a CD19xCD3 BiTE, for 
the treatment of relapsed or refractory B-precursor acute lympho-
blastic leukemia (ALL) (35, 36). DARTs, which have interchain 
disulfide bonds at their C-termini and are structurally compact, 
making them well suited for forming stable cell-to-cell contacts 
between target and effector cells, exhibit greater potency than 
BiTEs in side-by-side comparisons (32, 37).
Herein, we demonstrate the ability of HIVxCD3 DARTs 
to redirect CD8+ T cells against CD4+ cells infected by HIV-1, 
including ones infected with authentic latent virus isolates 
emerging from HIV-infected patients’ cells in model systems 
designed to mimic potential clinical HIV eradication strategies. 
The ability of HIVxCD3 DARTs to recognize conserved HIV-1 
antigens on infected cells and simultaneously engage receptors 
on the membrane of polyclonal effector T cells will overcome the 
need to activate preexisting HIV-specific cytotoxic effector cells 
(38), thus surmounting a crucial hurdle that impedes the effec-
tive elimination of the reservoir of infected CD4+ T cells.
Results
HIV arm selection for DARTs. A32 mAb binds to a conformational, 
CD4-inducible epitope in gp120 C1/C2 (within epitope cluster A) 
(28, 39–41), and 7B2 mAb binds to a linear epitope in gp41 cluster 
I (29, 30, 42). We tested these 2 mAbs for their ability to mediate 
ADCC against a panel of 22 representative HIV-1 infectious molec-
ular clones (IMCs) of subtypes A, AE, B, and C (Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI82314DS1). The A32 mAb recognized 21 (95%) 
disruption of latency and the induction of viral antigen expression 
in cells that are latently infected, is under intensive investigation 
(18, 19). However, as early progress is made in the development 
of latency reversing agents (LRAs), improvements in the ability to 
clear persistent infection must be sought, as well.
Latently infected cells are very rare, and even if the latent res-
ervoir is as much as 60 times larger than the typical estimates of 
about 1 infected cell per 106 resting central memory CD4+ cells 
(20), current LRAs might induce proviral transcription in only a 
fraction of this population, and the quantity of viral antigen pre-
sented might be low (21, 22). Therefore, a novel and robust immune 
response may be necessary to detect and clear both cells producing 
low-level viremia and in quiescently infected cells after inducing 
HIV-1 to leave the latent state.
Following the reactivation of latent HIV, viral antigens are 
presented on the surface of the cell and thus could be targeted by 
antibodies or antibody-derived molecules. Proof of concept for 
this approach has been provided by immunotoxins — bifunctional 
chimeric proteins consisting of a targeting domain, such as an anti-
body or a ligand, joined to a toxin effector domain (23). Although 
initial clinical trials using immunotoxins in HIV-infected individ-
uals failed to have sustained impact on immunological or clinical 
markers (24), immunotoxin 3B3-PE38 (25) has been reported to 
reduce levels of HIV-infected cells that persist despite ART in the 
BLT humanized mouse model (26).
Several mAbs have been reported as capable of recognizing HIV-1– 
infected cells and engaging Fc-γ receptor–bearing cells to mediate 
antibody-dependent cellular cytotoxicity (ADCC) (27), such as A32 
and 7B2, nonneutralizing mAbs that bind to conserved residues in 
gp120 (28) and gp41 (29, 30), respectively. Based on these proper-
ties, 2 Dual-Affinity Re-Targeting proteins (DART proteins) (31, 32) 
were generated in which HIV envelope targeting (Env-targeting) 
arms derived from the A32 and 7B2 mAbs were combined with a CD3 
effector arm derived from hXR32, a humanized anti-CD3ε mAb, to 
generate 2 HIVxCD3 DARTs: A32xCD3 and 7B2xCD3 (Figure 1).
Bispecific molecules that coengage T cells with antigen-
expressing target cells, such as DARTs and bispecific T cell engager 
Figure 1. HIVxCD3 DART structure. (A and B) These DART molecules 
contain an anti–HIV-1 binding arm (A32 or 7B2) combined with an anti-
CD3 binding arm (hXR32). They are composed of 2 polypeptide chains: 
one with the VL of anti-CD3 linked to the VH of anti-HIV; the second 
with the VL of anti-HIV linked to the VH of anti-CD3. The carboxy 
termini of the chains have an interchain disulfide bond and paired 
oppositely charged E-coil/K-coil dimerization domains. Control DARTs 
have one of the arms replaced by an irrelevant one derived from an anti-
FITC antibody (4420) or from an anti-RSV antibody, palivizumab (RSV) 
sequence. (C) Schematic representation of HIVxCD3 DART binding to 2 
distinct antigens simultaneously and redirecting the cytotoxic T cells 
(effectors) to lyse the Env-expressing, HIV-1–infected cells (targets).
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Table 2). Different Env proteins were utilized for these 2 DARTs in 
the SPR studies because A32xCD3 binding to JR-FL gp140 CF was 
inefficient and 7B2xCD3 binding to M.ConS gp140 CFI, due to its 
lack of the gp41 cluster I sequence, was precluded.
HIVxCD3 DARTs bind to their cell-surface antigens with 
specificity. DARTs with CD3 effector arms (A32xCD3, 7B2xCD3, 
4420xCD3) bind to human CD3+ T cells with similar efficiencies, 
whereas DARTs with the CD3 arm replaced by an irrelevant arm 
(A32x4420, 7B2x4420) or with 2 irrelevant arms (hBU12x4420) 
do not bind (Figure 2D). HIVxCD3 DARTs (A32xCD3, 7B2xCD3) 
bind efficiently to HEK293-D371 cells that express subtype AE 
CM244 Env (Figure 2E), and similar binding activity is observed 
with the A32x4420 and 7B2x4420 control DARTs (Supplemental 
Figure 3). As expected, the RSVxCD3 control DART does not bind 
to these cells (Figure 2E). A32xCD3 and 7B2xCD3 bind to Jur-
kat-522 F/Y cells, which express both CD3 and subtype B HXBc2 
Env (45), and binding via the CD3 arm predominates as shown 
by the equivalence of 4420xCD3, A32xCD3, and 7B2xCD3 bind-
ing. When the CD3 arm is replaced by the irrelevant 4420 arm to 
ablate CD3 binding, low-level binding to the cell-surface Env is 
detected with A32x4420, but not with 7B2x4420 (Figure 2F).
HIVxCD3 DART–redirected T cell killing of Env-expressing cell 
lines and concomitant T cell activation. Jurkat-522 F/Y is a human 
CD4+ cell line that expresses env and serves as a model for HIV- 
infected CD4+ T cells, and Jurkat-ΔKS is a control cell line that is 
identical, except for a deletion/frameshift mutation in the env gene 
that precludes its expression (45). These cell lines were utilized 
to evaluate the ability of HIVxCD3 DARTs to mediate redirected 
T cell killing of Env+ target cells. Target cell cytolysis was deter-
mined by measuring lactate dehydrogenase (LDH) release with our 
standard assay, and the results were confirmed by luminescence 
of the HIV-1 IMCs with an average percent specific lysis (%SL) of 
43.69% (range 12%–86%; Supplemental Figure 1). The 7B2 mAb 
recognized 20 (91%) of the HIV-1 IMCs with an average %SL of 
39.58% (range 15%–74%; Supplemental Figure 1). In addition to 
possessing breadth and efficiency in mediating ADCC — indicating 
epitope accessibility at the surface of HIV-infected cells, a necessary 
property for HIVxCD3 DARTs — the A32 and 7B2 mAbs are attrac-
tive sources for Env binding domains for DARTs, as the residues 
in Env that influence binding by these mAbs are highly conserved 
among all HIV-1 subtypes (Supplemental Figure 2). Based on these 
properties, 2 HIVxCD3 DARTs were generated in which HIV target-
ing arms derived from the A32 and 7B2 mAbs were combined with 
a CD3 effector arm derived from hXR32, a humanized anti-CD3ε 
mAb (Figure 1). These HIVxCD3 DARTs are named A32xCD3 and 
7B2xCD3. Control DARTs with an irrelevant arm — derived from an 
anti-FITC antibody (4420) or from palivizumab, an antibody to the 
respiratory syncytial virus (RSV) fusion protein antibody — instead 
of the HIV arm (4420xCD3, RSVxCD3) or CD3 arm (A32x4420, 
7B2x4420) were also generated.
HIV DART binding properties. A32xCD3 and 7B2xCD3 each 
exhibited binding to recombinant human CD3 and HIV-1 Env pro-
teins, individually and simultaneously, as shown by ELISA (Figure 
2, A–C). While the binding to CD3 protein was similar for both 
DARTs, the magnitude of binding to JR-FL gp140 CF was greater 
for 7B2xCD3 than for A32xCD3, likely due to the fact that the con-
formational A32 epitope is highly CD4 dependent (41–44). Based 
on surface plasmon resonance (SPR), the equilibrium dissociation 
constants (KD) for CD3 arm binding were 3.6 nM and 6.1 nM for 
A32xCD3 and 7B2xCD3, respectively; KD for HIV arm binding 
was 47.7 nM for A32xCD3 using M.ConS gp140 CFI, and 15.1 nM 
for 7B2xCD3 using JR-FL gp140 CF, respectively (Supplemental 
Figure 2. HIVxCD3 DART binding 
properties. (A–C) Antigen binding by 
ELISA. DART binding to human CD3 
protein (A), to JR-FL gp140 protein (B), 
or simultaneously to both JR-FL gp140 
and human CD3 proteins (C). (D–F) 
Cell-surface binding by flow cytome-
try analysis. DART binding to primary 
human T cells expressing CD3 (D); to 
HEK293-D371 cells expressing HIV-1 Env, 
CM244, subtype AE (E); or to Jurkat-522 
F/Y cells expressing CD3 and HIV-1 Env, 
HXBC2, subtype B (F). Data are reported 
as mean fluorescence intensity (MFI). 
CD3 and Env expression characteristics 
of the cells are reported in parenthe-
sis. A32 and 7B2 are targeting arms 
that recognize HIV-1 gp120 and gp41, 
respectively; CD3 is the effector arm 
that recognizes CD3ε; and hBU12, 
RSV, and 4420 are irrelevant, negative 
control arms.
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ination of the Env+ target cells was nearly complete (>98%), while 
the 4420xCD3 control DART mediated no cytotoxicity (Figure 3D). 
HIVxCD3 DART–redirected T cell–killing activity was time and 
E/T ratio dependent. Near complete cytolysis with 7B2xCD3 was 
reached at 48 hours at E/T ratios of 10:1 and 5:1, whereas high-level 
cytolysis (>80%) at an E/T ratio of 1:1 was delayed until 72 hours 
(Figure 3, E–H), suggesting that time is the limiting factor for the 
efficient elimination of target cells at lower E/T cell ratios.
Concomitant with redirecting T cell–killing activity, the 
HIVxCD3 DARTs induced T cell activation (measured by upregu-
lation of the activation marker CD25) in the presence of the Env+ 
target cells, with CD25 upregulated in CD8+ T cells to a greater 
extent than in CD4+ T cells (Supplemental Figure 4). The overall 
data demonstrate that A32xCD3 and 7B2xCD3 potently activate 
and redirect T cells, especially CD8+ T cells, to specifically kill 
Env-expressing target cells. Moreover, the killing data confirm 
that both DARTs were capable of recognizing and binding to Env 
antigens on the surface of a CD4+ cell line, even though the detec-
tion of Env binding by FACS analysis was negligible (Figure 2F).
HIVxCD3 DARTs bind to the surface of HIV-1–infected CD4+ 
T cells and redirect CD8+ T cells to kill HIV-1–infected CD4+ cells 
(LUM) assay. As measured by LDH release assays, A32xCD3 and 
7B2xCD3 redirected human T cells derived from healthy donors to 
kill the Jurkat-522 F/Y cells in a concentration-dependent manner 
at an effector/target cell ratio (E/T ratio) of 10:1, and these 2 HIVx-
DARTs exhibited similar potencies after 48 hours of incubation 
with 50% effective concentrations (EC50) of 160–230 pg/ml (Fig-
ure 3A). No DART-mediated redirected T cell killing of Jurkat-522 
F/Y cells occurred with control DARTs (4420xCD3, A32x4420, 
7B2x4420) in which the HIV arm or CD3 arm was replaced by an 
irrelevant one (Figure 3A). The A32xCD3 and 7B2xCD3 DARTs 
did not mediate target-cell killing when the effector T cells were 
omitted (Figure 3B) or when the target cells lacked Env expression 
(Figure 3C). These data demonstrate a strict requirement for Env-
expressing target cells and their coengagement with CD3-express-
ing effector cells for HIVxCD3 DART–mediated cytolytic activity.
As measured by LUM assays, A32xCD3 and 7B2xCD3 exhibited 
similar potencies for redirected T cell killing of Jurkat-522 F/Y GF 
cells with EC50 values of 140–170 pg/ml (Figure 3D), which were 
close to those measured with the LDH release assay, indicating con-
sistency across the 2 different assay modalities. Moreover, with the 
sensitivity and specificity of the LUM assay, DART-dependent elim-
Figure 3. HIVxCD3 DART–redirected T cell killing of Env+ target cells. (A) DART concentration–dependent killing of Env+ Jurkat-522 F/Y cells in the pres-
ence of human T cells at an E/T ratio of 10:1 for 48 hours with cytolysis measured by LDH release assay; EC50 values were 230 and 160 pg/ml for A32xCD3 
and 7B2xCD3, respectively. The control DARTs (A32x4420, 7B2x4420, 4420xCD3) were inactive. (B) Lack of DART-mediated killing of Env+ Jurkat-522 F/Y 
cells in the absence of effector T cells with cytolysis measured by LDH release assay. (C) Lack of DART-redirected T cell killing of Env– Jurkat ΔKS cells at an 
E/T ratio of 10:1 for 48 hours with cytolysis measured by LDH release assay. (D) DART concentration–dependent killing of Env+ Jurkat-522 F/Y GF cells in 
the presence of human T cells at an E/T ratio of 10:1 for 48 hours with cytolysis measured by LUM assay; EC50 values were 172 and 147 pg/ml for A32xCD3 
and 7B2xCD3, respectively. (E–G) 7B2xCD3 DART concentration–dependent redirected T cell killing of Env+ Jurkat-522 F/Y GF cells at different E/T ratios 
(10:1, 5:1, 1:1) and incubation times (24, 48, 72 hours) with cytolysis measured by LUM assay. (H) Time course of maximal cytolytic activity with 7B2xCD3 at 
different E/T ratios (data from E–G).
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against autologous CD4+ T cells infected with the 3 HIV-1 IMCs. 
The 2 HIVxCD3 DARTs redirected autologous CD8+ T effector 
cells to kill subtype B BaL (Figure 4A), subtype AE CM235 (Fig-
ure 4B), and subtype C 1086.C (Figure 4C) IMC-infected CD4+ 
target cells in a concentration-dependent manner, whereas the 
control DART (4420xCD3) was inactive. The greater potency 
exhibited by A32xCD3 (EC50 ≤ 1 ng/ml) compared with 7B2xCD3 
(EC50 ~10 ng/ml) in these studies with IMC-infected CD4
+ cells 
contrasts with the similar potencies observed in the studies 
with Env+ cell lines (Figure 3, A–C). DART-mediated killing of 
the IMC-infected CD4+ T cells was dependent on the presence 
of CD8+ effector cells, and no cytolytic activity was observed in 
their absence (Figure 4, A–C). In time-course studies, DART- 
dependent cytolytic activity was evident at 6 hours with maximal 
activity (>70% cytolysis) at 48 hours (Figure 4, D–F).
To gain insight into the frequency of effector T cells recruited 
by the DARTs to kill HIV-1–infected target cells, we assessed the 
ability of DARTs to induce degranulation of the CD8+ T cells 
obtained from 5 HIV-1 seronegative donors when coincubated with 
autologous HIV-1 BaL IMC-infected CD4+ cells under the same 
conditions used to detect cytolytic activity. The example of the 
gating strategy adopted for data analysis is illustrated in Figure 5, 
using lymphocytes from HIV-1 seronegative donors. We evaluated 
the A32x4420 and 7B2x4420 DARTs for their ability to bind 
and redirect the killing of CD4+ T cells infected with HIV-1 IMCs 
representing subtype AE CM235, subtype B BaL, and subtype C 
1086.C HIV-1 isolates. Each IMC was engineered with a luci-
ferase reporter gene to quantitatively measure the cytolysis of 
infected target cells. To assess binding to infected cell-surface 
Env, A32x4420 and 7B2x4420 DARTs (which lack CD3 effector 
arms) were compared with the parental A32 and 7B2 mAbs. We 
observed similar staining of the p24+ (infected) CD4+ T cells by 
both HIVxCD3 DARTs independently from the HIV-1 IMC used 
for the infection (Supplemental Figure 5). Interestingly, staining 
with the A32x4420 DART recapitulated closely the staining with 
the A32 mAbs; in contrast, the 7B2x4420 DART recognized >66% 
of the HIV-1–infected cells (range 66%–78%) compared with the 
>24% recognized by the 7B2 mAb (range 24%–38%), suggest-
ing that the DART has a better accessibility to the cluster I gp41 
epitope compared with the mAb (Supplemental Figure 5). The sec-
ondary conjugated antibodies and the palivizumab mAb utilized 
as controls recognized less than 5% HIV-1–infected CD4+ T cells.
We subsequently investigated the ability of A32xCD3 and 
7B2xCD3 to redirect CD8+ T cells from HIV-1 seronegative donors 
Figure 4. HIVxCD3 DARTs redirect T cell cytotoxicity against CD4+ cells infected with HIV-1 IMCs of different subtypes. (A–C) DART-concentration 
dependence. Activated CD4+ T cells from a HIV-1 seronegative donor were infected with HIV-1 subtype B BaL (A), subtype AE CM235 (B), or subtype C 
1086.C (C) IMC and incubated for 48 hours with A32xCD3 (red circles), 7B2xCD3 (blue squares), or 4420xCD3 (black diamonds) in the presence of autolo-
gous resting CD8+ T cells at an E/T ratio of 33:1 (filled symbols) or in the absence of effector cells (E/T ratio of 0:1) (open symbols). The data are reported 
as %SL. DART concentrations ranged from 0.001–1,000 ng/ml. (D–F) Time course. The data represent the maximal %SL observed at 6, 24, and 48 hours 
for each DART against CD4+ T cells infected infected with HIV-1 subtype B BaL (D), subtype AE CM235 (E), or subtype C 1086.C (F) IMC and incubated with 
autologous resting CD8+ T cells at an E/T ratio of 33:1.
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A–G. The mean frequency of live/CD3+/CD8+/CD107+ cells (Fig-
ure 5H) under control conditions (absence of HIVxCD3 DART or 
presence of control DART) was 0.38% (standard deviation 0.10%; 
range 0.24%–0.51%), which increased to an average 3.53% (range 
1.5%–6.9%) or 18.23% (range 12.30%–23.35%) in the presence of 
1 ng/ml 7B2xCD3 or A32xCD3, respectively. The data demon-
strate that HIVxCD3 DARTs can specifically induce degranulation 
of resting CD8+ T cells in the presence of Env-expressing target 
cells (autologous HIV-1–infected CD4+ T cells).
HIVxCD3 DART–redirected CD8+ T cell–killing activity against 
JR-CSF–infected cells from seronegative donors. A viral clearance 
assay measuring HIV gag p24 antigen production was utilized as an 
alternative method to assess DART-redirected T cell–killing activ-
ity. CD4+ cells from healthy donors were superinfected with the 
HIV-1 clade B clone JR-CSF and incubated with autologous CD8+ T 
cells at an E/T ratio of 1:1 in the absence or presence of 100 ng/ml 
DARTs for 7 days. In experiments with 2 different donors, addition 
of the control DART (4420xCD3) did not significantly reduce p24 
production compared with incubations performed in the absence 
of DARTs, whereas addition of A32xCD3 or 7B2xCD3 signifi-
cantly reduced p24 production to a similar extent (by 72%–96% or 
87%–99%, respectively; P < 0.05 Dunnett’s test for multiple com-
parisons; Figure 6, A and B). The viral clearance assay was also 
conducted in the presence of integrase and nonnucleoside reverse 
transcriptase inhibitors once infection was established, at the time 
of addition of effector cells and DARTs, to block further rounds of 
infection. When antiretrovirals (ARVs) were included in the assay, 
A32xCD3 and 7B2xCD3 still mediated a trend toward reduction 
Figure 5. HIVxCD3 DARTs induce specific degranulation of CD8+ T cells. (A–D) Schematic of gating strategy to identify live/CD3+CD8+CD107+ T cells after their 
incubation with HIV-1 BaL–infected target cells in the presence of DARTs for 6 hours. (E–G) Dot plots represent the percentage of live/CD3+CD8+CD107+ cells 
observed in the presence of 1 ng/ml of 4420xCD3 (E), 7B2xCD3 (F), or A32xCD3 (G). (H) Frequency of the CD3+CD4–CD8+CD107+ T cells observed in each of the 5 
HIV-1 seronegative healthy donors after 6 hours of incubation with the autologous infected CD4+ T cells using the E/T ratio of 33:1. Each symbol represents the 
average of duplicate stimulations performed for each donor. The lines represent the mean ± SD. *P < 0.05 after Dunnett’s test for multiple comparisons.
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in p24 production. This did not reach statistical significance, likely 
due to low levels of baseline p24 production with the ARVs (Figure 
6C), suggesting that the DARTs are not acting by inhibition of virus 
spread but rather through clearance of infected cells.
HIVxCD3 DARTs redirect CD8+ T cells to clear JR-CSF–superin-
fected CD4+ cells using lymphocytes from patients on suppressive ART. 
Chronic ART is characterized by dysfunctional and exhausted T cell 
responses (46, 47) and thus confirmation of robust DART-mediated 
T cell–redirected clearance activity in patient samples ex vivo is crit-
ical. We therefore evaluated the activity of HIVxCD3 DARTs in viral 
clearance assays with lymphocytes from 8 HIV-infected individu-
als on suppressive ART. All participants were on ART for at least 6 
months at the time of study with virus load <50 copies/ml but other-
wise exhibited diverse clinical backgrounds (Supplemental Table 3).
Because T cells from HIV-1 seropositive subjects could be 
more susceptible to apoptosis than those from seronegative sub-
jects (48), we first evaluated whether HIVxCD3 DARTs, in the 
absence of target cells, might impact T cell viability, which could 
confound the analysis of DART activity with patients’ cells. Fol-
lowing 7 days of culture of either CD4+ or CD8+ T cells from 
HIV-infected, ART-suppressed patients in the presence of 100 
ng/ml DART, which mimics the viral clearance assay conditions, 
we did not observe decreases in T cell viability based on Annexin 
V/7-amino-actinomycin D (7 AAD) staining (Supplemental Figure 
6, A and B). Moreover, no changes in activation markers (HLA-
DR, CD25) on unstimulated CD4+ or CD8+ T cells were observed 
after culture with HIVxCD3 or control DARTs (Supplemental Fig-
ure 6, C and D), suggesting that engagement of the CD3 arm alone 
does not activate patients’ CD8+ or CD4+ T cells ex vivo.
Using the lymphocytes from 8 HIV-1–infected patients on 
suppressive ART, viral clearance assays were conducted in which 
CD4+ cells were superinfected with HIV-1 JR-CSF (target cells) 
and incubated with autologous CD8+ cells (effectors) at E/T ratios 
of 0:1, 1:10, or 1:1 in the absence or presence of 100 ng/ml DARTs 
for 7 days. HIVxCD3 DART activity occurred even in the absence 
of added CD8+ T cells, indicating that, under these experimental 
conditions, CD4+ T cells may be recruited as effector cells; com-
pared with control, p24 production was reduced by 0.89 log with 
7B2xCD3 (P < 0.05), by 0.32 log with A32xCD3 (P = NS), and 
by 0.81 with a 1:1 cocktail of both DARTs (P < 0.05) (Figure 7A). 
Indeed, the addition of fully active DARTs led to significantly 
increased degranulation of CD4+ T cells when in the presence of 
infected target cells (Figure 7, G and H). The addition of CD8+ 
T cells as effectors resulted in further reductions in p24 levels; com-
pared with the 0.13 log reduction seen with CD8+ T cells alone at an 
E/T of 1:10, p24 production was reduced by 1.2 log with 7B2xCD3 
(P < 0.05), by 0.6 log with A32xCD3 (P = NS), and by 1.8 log with a 
cocktail of the 2 DARTs (P < 0.05) (Figure 7B). Even more marked 
reductions were found with the higher E/T ratio of 1:1, where CD8+ 
T cells alone accounted for a 0.7 log reduction, but p24 production 
was reduced by 2.8 log with 7B2xCD3 (P < 0.05), by 1.6 log with 
A32xCD3 (P = NS), and by 2.8 log with a cocktail of the 2 DARTs 
(P < 0.05) (Figure 7C). Significant reductions were seen even in 
the absence of any detectable baseline CD8+ T cell antiviral activ-
ity, and in 3 cases, no virus was able to be recovered following 
incubation with DARTs (patient 749 with both fully active DARTs, 
and patients 720 and 725 with 7B2xCD3). The absolute HIV gag 
p24 antigen values are provided in Supplemental Table 4.
HIVxCD3 DARTs redirect CD8+ T cells to clear autologous reser-
voir virus–superinfected CD4+ cells using lymphocytes from patients 
on suppressive ART. We evaluated the ability of the DARTs to redi-
rect T cells against target cells expressing env sequences arising 
from the latent reservoir through the use of viral clearance assays 
employing autologous reservoir virus–infected (AR virus–infected) 
CD4+ target cells from 5 patients (Figure 7, D–F). Patient AR virus 
isolates were generated from pooled supernatants of limiting dilu-
tion cultures of mitogen-stimulated resting CD4+ T cells to reflect 
the diversity of virus that may be encountered in vivo following 
reactivation of latent virus. Despite the diversity of the AR virus 
isolates, DART activity mirrored that seen with JR-CSF–infected 
target cells. Modest activity was observed with AR-infected target 
cells in the absence of CD8+ effectors (thus attributed to CD4+ T 
cells; Figure 7D), with p24 production reduced by 0.32 log with 
7B2xCD3 and by 0.20 log with A32xCD3 (P = NS due to higher 
variance in response to 7B2xCD3) and by 0.51 log with a 1:1 cocktail 
of both DARTs (P < 0.05), whereas no activity was observed with 
Figure 6. Viral clearance assay to assess HIVxCD3 DART redirected CD8+ T cell killing of autologous JR-CSF–infected CD4+ T cells from healthy HIV 
seronegative donors. Activated CD4+ T cells from HIV seronegative donors were infected with HIV-1 clone JR-CSF and then incubated with autologous 
resting CD8+ T effector cells at an E/T ratio of 1:1 in the absence (No DART) or presence of HIVxCD3 or control DARTs at a concentration of 100 ng/ml for 7 
days. Results are shown for 2 healthy donors (A and B), as well as for healthy donor 2 in the presence of integrase and nonnucleoside reverse transcriptase 
inhibitors during the coculture period to inhibit virus replication (C). Each bar represents the absolute p24 concentration detected in culture supernatants. 
Error bars represent standard error mean (± SEM) of n = 3. *P < 0.05 with Dunnett’s test for multiple comparisons.
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Figure 7. Viral clearance assay detects HIVxCD3 DART–redirected 
CD8+ T cell clearance of JR-CSF– or AR virus–infected CD4+ cells 
using lymphocytes from HIV-infected ART suppressed patients. 
CD4+ depleted T cells from HIV-infected, ART-suppressed patients 
were activated with PHA and infected with HIV-1 subtype B clone 
JR-CSF (A–C) or AR virus isolates (D–F), and then incubated without 
(A and D) or with autologous CD8+ T effector cells at E/T ratios of 
1:10 (B and E) or 1:1 (C and F) in the absence (No DART) or presence 
of HIVxCD3 (A32xCD3, 7B2xCD3) or control (7B2x4420, 4420xCD3) 
DARTs at a concentration of 100 ng/ml for 7 days. Combo indicates a 
1:1 cocktail of 7B2xCD3 and A32xCD3 at a total concentration of 100 
ng/ml. Each bar represents the log-fold reduction of p24 detected 
in culture supernatants, calculated as the log (p24 levels of infected 
target cells divided by p24 levels of the test condition). (G) Schematic 
of gating strategy to identify live/CD3+CD4+CD107+ effector (TFL4–) 
T cells after their incubation with HIV-1 JR-CSF–infected target cells 
in presence of DARTs for 6 hours. (H) The percentage of live/effector 
cells (TFL4–)/CD3+/CD4+/107a+ cells following a 6-hour incubation 
with the indicated DARTs and JR-CSF–infected targets in n = 4 
patients. Error bars represent ± SEM of n = 8 (A–C, except for combo 
[n = 5] and 7B2x4420 [n = 6]), n = 5 (D–F), and n = 4 (G and H).  
*P < 0.05 with Dunnett’s test for multiple comparisons.
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gen as they emerge from latency. We therefore employed a latency 
clearance assay (LCA) as previously described (49). This assay 
seeks to measure the ability of DARTs to redirect autologous CD8+ 
T cells to reduce viral recovery following induction of resting CD4+ 
T cells of HIV-infected individuals on suppressive ART. Addition 
of fully active DARTs or a 1:1 cocktail of A32xCD3 and 7B2xCD3 
to a coculture of CD8+ T cells with PHA-stimulated resting CD4+ T 
cells at an E/T ratio of 1:10 reduced viral recovery in all 6 patients, 
although the magnitude of reduction varied among patients (Fig-
ure 8A and Supplemental Table 5).
Reversal of HIV latency using maximal mitogen stimulation 
in vivo is not clinically practical (50). However, the presentation of 
viral antigen following the reversal of latency with agents that do 
not result in global T cell activation, such as vorinostat (VOR), may 
be less robust than that following maximal mitogen stimulation. 
To evaluate the HIVxCD3 DARTs in a clinically relevant context, 
we used a physiologically relevant exposure to VOR that models 
the exposure obtained following a single 400 mg in vivo dose (18) 
to induce latent viral envelope expression. In this setting, addition 
the control DARTs (Figure 7D). The addition of HIVxCD3 DARTs 
to a mixture of AR virus–infected CD4+ target cells and autologous 
CD8+ effector cells led to significantly enhanced reductions in p24 
production. At an E/T ratio of 1:10, p24 production was reduced 
by 0.51 log with 7B2xCD3 (P < 0.05), by 0.37 log with A32xCD3, 
and by 0.79 log with a 1:1 cocktail of the 2 (P < 0.05), compared 
with a reduction of only 0.02 log with CD8+ cells alone (Figure 
7E). A trend toward decreased p24 production in the presence 
of HIVxCD3 DARTs was also seen at the higher E/T ratio of 1:1, 
although the magnitude of the effect was reduced by the variable 
baseline CD8+ activity seen in the absence of DARTs (Figure 7F). 
Notably, ex vivo DART activity was observed with lymphocytes 
from all 5 patients evaluated with at least one of the 2 HIVxCD3 
DARTs and in all cases with the 1:1 DART cocktail.
HIVxCD3 DARTs redirect T cells from HIV-infected individuals 
on suppressive ART to clear virus from resting CD4+ T cells following 
induction of latent virus expression. Ultimately, a reagent used in 
the “shock and kill” HIV eradication strategy must recognize and 
clear rare infected cells that are likely to express low levels of anti-
Figure 8. LCA to assess HIVxCD3 DART–
redirected CD8+ T cell activity. Resting CD4+ 
T cells from HIV-infected, ART-suppressed 
patients were incubated with PHA (A) or 
VOR (B), plated in 12–36 replicate wells 
depending on the size of the patient’s 
latent reservoir, and cocultured with 
autologous CD8+ T cells at an E/T ratio of 
1:10 in the absence or presence of HIVxCD3 
or control DARTs at 100 ng/ml for 24 
hours (or up to 96 hours where indicated), 
after which DARTs were washed off and 
CD8-depleted PBMCs from a seronegative 
donor were added to amplify residual virus. 
Wells were assessed for the presence or 
absence of p24 by ELISA at day 15. Combo 
indicates a 1:1 cocktail of 7B2xCD3 and 
A32xCD3 at a total concentration of 100 
ng/ml. Results are shown as percent viral 
recovery (number of positive wells/total 
number plated), normalized to a control in 
which no CD8+ T cells are added. Dashed 
lines indicate undetectable viral recovery 
following incubation with combo DARTs, 
except for patient 408 in panel B, where 
they indicate undetectable viral recovery 
after 7B2xCD3 or A32xCD3 individually. NT 
indicates conditions not tested due to low 
cell availability. NT generally refers to 2 
conditions not tested (7B2xCD3 or A32xCD3 
individually), except for patient 408 in panel 
B, where NT refers to combo DARTs not 
tested. Refer to Supplemental Table 5 for 
the individual experimental values for each 
of the conditions tested.
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were capable of increasing degranulation of CD4+ T cells when 
cocultured with infected autologous target cells from HIV+ indi-
viduals. Cytotoxic CD4+ T cells have been previously reported in 
the context of responses to HIV-1 (56) and cytomegalovirus (57). 
Further studies will be necessary to determine whether effec-
tive DART recruitment and redirection of cytotoxic CD4+ T cells 
occurs under in vivo settings.
The relative potencies of the A32xCD3 and 7B2xCD3 DARTs 
varied among the different test systems employed in our studies, 
most likely due to variations in the characteristics of the Env-
expressing target cells and/or effector T cells. However, whenever 
one of the DARTs exhibited greater activity than the other, we con-
sistently observed activity similar to that of the more potent DART 
when combinations of the 2 DARTs were utilized in the studies with 
infected patients’ cells (Figures 7 and 8). Thus, combinations of 
DARTs targeting different HIV epitopes may be an advantageous 
strategy to maximize both level and breadth of activity, similar to 
what has been described for combinations of ADCC-mediating 
(58) or broadly neutralizing anti–HIV-1 mAbs (59, 60).
Eliminating the pool of latently infected cells by HIV-1– 
specific CD8+ T cell responses is limited by the low frequency of 
these cells in infected individuals and the need to activate them 
from the resting state (38). With resting CD8+ T cells from HIV-1 
seronegative individuals lacking any previous exposure to HIV-1 
antigens, HIVxCD3 DARTs induced degranulation of up to 23% 
of these resting CD8+ T cells when incubated with the autologous 
HIV-1–infected target cells destined to be killed. DARTs were also 
capable of redirecting CD8+ T cells from HIV-1 seropositive indi-
viduals who received ART in viral clearance assays. Therefore, 
HIVxCD3 DART proteins can effectively recruit and redirect 
CD8+ T cytotoxic cells independently of previous exposure to HIV 
antigens and regardless of any functional impairment that may 
remain in chronic HIV-1 infection (46, 47, 61).
DART-redirected T cell activity against HIV-1 Env-expressing 
targets was dependent on HIVxCD3 DART concentration, E/T 
ratio, and incubation time. The monovalent nature of each of the 
binding arms of the HIVxCD3 DART molecule ensures that tar-
get-cell killing depends exclusively on E/T cell coengagement, 
as has been observed with CD19xCD3 and other DARTs (31, 32, 
34). No HIVxCD3 DART–mediated T cell activation or redirected 
killing activity was observed in the absence of Env expression on 
target cells. Similarly, with T cells from HIV-infected patients on 
suppressive ART, no T cell activation was observed in the absence 
of virus-infected target cells. Because they should elicit cytotoxic 
activity from circulating T cells only in the proximity of HIV-1– 
infected Env-expressing target cells, HIVxCD3 DARTs are not 
expected to elicit widespread systemic effects, such as inflamma-
tory cytokine release, in HIV-infected patients on ART due to the 
scarcity of the Env-expressing target cells. The specificity of T cell 
redirected responses elicited by HIVxCD3 DARTs will be of criti-
cal importance clinically, considering that HIV infection induces 
nonspecific activation of the immune system in both the acute and 
chronic phases of the disease in HIV-1–specific T cell subsets, as 
well as in general CD8+ T cell populations (62–64).
HIV-infected CD4+ T cells expressing cell-surface Env are 
the primary in vivo targets for HIVxCD3 DART–redirected T cell–
killing activity. Because these target cells also express CD3, the 
of CD8+ T cells at an E/T ratio of 1:10 plus fully active DARTs led to 
a reduction in viral recovery following a 24-hour coculture period 
when compared with CD8+ T cells with or without control DARTs 
in 4 of 5 patients tested. In the single patient who did not respond 
to DARTs after a 24-hour coculture period (patient 795), extend-
ing the coculture period from 24 hours to 96 hours led to complete 
ablation of viral recovery (Figure 8B and Supplemental Table 5).
Discussion
Crucial hurdles in the elimination of the latent HIV-1 reservoir 
include: (i) the limited ability of the immune system to recognize 
rare HIV-1–infected cells presenting modest levels of HIV antigen 
prior to or following induction with LRA (38, 51); (ii) the presence 
of CD8+ cytotoxic T lymphocyte escape mutants in the HIV-1 
latent reservoir (52); and (iii) the low frequency of circulating 
HIV-specific CD8+ T cells in patients on ART and the necessity to 
activate them due to inadequate stimuli provided by infected cells 
(38). In this study, we present data that HIVxCD3 DARTs could 
overcome each of these major obstacles.
HIVxCD3 DARTs with HIV arms derived from the nonneu-
tralizing mAbs A32 and 7B2 were able to recognize HIV-1 Env–
expressing cell lines and to elicit redirected T cell–killing activity, 
even when cell-surface Env expression appeared low. In addition, 
HIVxCD3 DARTs were effective ex vivo in redirecting CD8+ T 
cells to clear resting CD4+ T cells obtained from aviremic, ART-
treated patients following exposure to VOR.
HIV-1 isolates represented in the latent reservoir are reported 
to include escape mutants generated by the CD8+ T cell responses 
(52), which may limit the ability of the MHC class I–restricted 
CD8+ CTL responses induced by natural infection to clear HIV-1– 
infected cells. The A32 and 7B2 arms of the HIVxCD3 DARTs 
are based on broadly reactive nonneutralizing anti-HIV mAbs 
that interact with highly conserved residues in gp120 and gp41, 
respectively, and efficiently mediate ADCC activity against cells 
infected with HIV-1 isolates of various subtypes. Of note, the A32 
mAb epitope is the earliest one known to be expressed on the sur-
face of infected cells during the syncytia formation process (53) or 
following tier 2 virus infection (54), and the 7B2 mAb epitope is 
accessible on gp41 stumps, which are expressed on the surface of 
infected cells during budding and retained at the membrane sur-
face when gp120 subunits dissociate (29, 55). These properties are 
indicative of the accessibility of the A32 and 7B2 epitopes on the 
surface of infected cells. Importantly, the existence of CTL escape 
mutants is not a limitation because CTL epitopes are irrelevant 
to DART-mediated redirected killing activity. Further, effector T 
cells recruited by bispecific molecules like DARTs are polyclonal 
and not MHC-restricted (33). Consistent with these assertions, 
A32xCD3 and 7B2xCD3 were effective at redirecting CD8+ T 
cells from patients to clear CD4+ cells infected by their own AR 
virus, regardless of the presence of any escape mutations that may 
have accumulated before initiation of therapy (52). Interestingly, 
upon in vitro activation of the CD4+ T cells used as target cells, we 
observed a specific reduction in virus recovery in the absence of 
CD8+ T cells, suggesting that DARTs could also recruit cytotoxic 
CD4+ T cells under these particular experimental conditions. In 
line with these, we found that DARTs induced activation of CD4+ 
T cells in the presence of Env-expressing Jurkat-522 F/Y cells, and 
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fected into CHO cells, and proteins were purified as described previ-
ously (31). Purified proteins were analyzed by SDS-PAGE (NuPAGE 
Bis-Tris gel system, Invitrogen) and analytical SEC (TSK GS3000S-
WxL SE-HPLC, Tosoh Bioscience).
ELISA. For monospecific binding assays, a MaxiSorp microtiter 
plate (Nunc) coated with recombinant proteins (human CD3ε/δ het-
erodimer, JR-FL gp140ΔCF; ref. 70) in bicarbonate buffer was blocked 
with 3% BSA and 0.1% Tween-20. DART proteins were applied, fol-
lowed by sequential addition of biotinylated anti-EK coil antibody and 
streptavidin-HRP (BD Biosciences). For bispecific binding assays, the 
plate was coated with JR-FL gp140ΔCF, and DART application was fol-
lowed by sequential addition of biotinylated CD3ε/δ and streptavidin- 
HRP. HRP activity was detected with SuperSignal ELISA Pico chemi-
luminescent substrate (Thermo Scientific).
SPR analysis. HIVxCD3 DART binding to antigens was analyzed 
by BIAcore 3000 biosensor (GE Healthcare) as previously described 
(31, 32). Human CD3ε/δ was immobilized on the CM5 sensor chip 
according to the manufacturer’s procedure. DART binding to immo-
bilized CD3 was analyzed to assess the properties of the CD3 arm, 
and HIV-1 Env protein binding to HIV DART captured on immo-
bilized CD3 was analyzed to assess the properties of the HIV arm. 
JR-FL gp140CF was used to assess 7B2xCD3 binding, and M.ConS 
gp140ΔCFI (70) was used to assess A32xCD3 binding. The different 
Env proteins were utilized because A32xCD3 did not bind efficiently 
to JR-FL gp140ΔCF and M.ConS gp140ΔCFI lacks the gp41 binding 
site for 7B2xCD3. Binding experiments were performed in 10 mM 
HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% P20 surfac-
tant. Regeneration of immobilized receptor surfaces was performed 
by pulse injection of 10 mM glycine. pH 1.5. KD values were deter-
mined by a global fit of binding curves to the Langmuir 1:1 binding 
model (BIAevaluation software v4.1).
Cell lines. Jurkat-522 F/Y GF cells, which constitutively express a 
fusion protein of copepod GFP (copGFP) and firefly luciferase (System 
Biosciences Inc.), were generated at Macrogenics from Jurkat-522 F/Y 
cells by transduction and clone selection. HEK293-D371 cells, which 
have doxycycline-inducible expression of HIV-1 CM244 (subtype AE) 
gp140, were obtained from John Kappes (University of Alabama at Bir-
mingham, Birmingham, Alabama, USA).
Flow cytometric analysis of DART or mAb binding to cells. DARTs 
at 4 μg/ml were incubated with 105 cells in 200 μl FACS buffer con-
taining 10% human AB serum for 30 minutes at room temperature. 
After washing, cells were resuspended in 100 μl of 1 μg/ml biotin-con-
jugated mouse anti-EK antibody (recognizes the E/K heterodimeriza-
tion region of DART proteins; MacroGenics), mixed with 1:500 
diluted streptavidin-PE (BD Biosciences) and incubated in the dark for 
45 minutes at 28°C–8°C. Cells were washed, resuspended with FACS 
buffer, and analyzed with a BD Calibur flow cytometer and FlowJo 
software (Tree Star Inc.). Binding to IMC-infected CD4+ T cells from 
normal human donors was conducted as previously described (54) for 
the A32 and 7B2 mAbs, and with biotin-conjugated mouse anti-EK 
antibody and 1:500 diluted streptavidin-PE for the HIVx4420 DARTs.
Redirected T cell cytotoxicity assay against HIV-1 Env–expressing 
cell lines and assessment of T cell activation. Pan T cells were iso-
lated from healthy human PBMCs with the Dynabeads Untouched 
Human T Cells Kit (Invitrogen). HIV-1 Env–expressing cell lines 
(1–4 × 105 cells/ml) were treated with serial dilutions of DARTs, 
together with human T cells at an E/T ratio of 10:1, or otherwise 
DART molecules could mediate synapses between infected and 
uninfected CD4+ T cells that, rather than or in addition to redi-
recting the killing of infected cells, conceivably could facilitate the 
spread of virus to uninfected cells. However, we did not observe 
any evidence to suggest that DARTs enhanced the spread of virus, 
as DARTs reduced p24 production even in the absence of CD8+ 
T cells (Figure 7, A and D).
In summary, our experiments demonstrate that HIVxCD3 
DARTs, with HIV arms derived from the nonneutralizing A32 
and 7B2 mAbs, are specific and potent agents to redirect cytolytic 
T cells against target cells consisting of (i) HIV-1 Env–express-
ing CD4+ cell lines, (ii) activated CD4+ cells from seronegative 
individuals infected with HIV-1 IMCs of different subtypes, (iii) 
activated CD4+ cells from seropositive patients on suppressive 
ART infected with JR-CSF or AR virus, or (iv) resting CD4+ cells 
from HIV-infected patients exposed ex vivo to a T cell mitogen 
(phytohemagglutinin, PHA) or LRA (VOR). Importantly, the 
studies demonstrated that autologous CD8+ T cells from HIV- 
infected patients on suppressive ART were efficacious as effector 
cells in the presence of DARTs. The demonstration of HIVxCD3 
DART–mediated T cell–killing activity in the presence of VOR 
is particularly notable because it provides evidence of activ-
ity against authentic latent virus isolates expressed from HIV- 
infected patients’ cells in a model system designed to mimic poten-
tial clinical HIV eradication strategies, similar to earlier findings 
using ex-vivo expanded CTLs (49). Thus, our data indicate that 
HIVxCD3 DARTs are suitable agents for testing in vivo in combi-
nation with LRAs in “shock and kill” HIV eradication strategies.
Methods
IMCs. HIV-1 IMCs for subtype B BaL, subtype AE CM235, and subtype 
C 1086.C were generated with the backbone derived from NHL4-3 
isolate as previously described (65, 66). All IMCs expressed the Renilla 
luciferase reporter gene and preserved all 9 viral open reading frames. 
The Renilla luciferase reporter gene was expressed under the control 
of the HIV-1 Tat gene. Upon HIV-1 infection of CD4+ T cells, expres-
sion of Tat during HIV-1 replication will induce luciferase expression, 
which allows quantitation of infected cells by measuring relative lumi-
nescence units (RLU).
Construction, expression, and purification of HIVxCD3 DARTs. The 
DARTs were produced from plasmids that coexpressed 2 polypeptide 
chains: one with light chain variable domain (VL) of anti-CD3 linked 
to heavy chain variable domain (VH) of anti-HIV and the second with 
VL of anti-HIV linked to VH of anti-CD3. The carboxy termini of the 2 
polypeptide chains consist of paired oppositely charged E-coil/K-coil 
dimerization domains, which include an interchain disulfide bond 
(Figure 1). The HIV arm sequences were derived from the nonneu-
tralizing mAbs, A32 (GenBank accession numbers 3TNM_H and 
3TNM_L) and 7B2 (GenBank accession numbers AFQ31502 and 
AFQ31503), and the CD3 arm sequence was derived from hXR32, a 
humanized mouse anti-human CD3ε mAb (L. Huang, L.S. Johnson, 
CD3-binding molecules capable of binding to human and nonhuman 
CD3, US Patent. 20140099318 (2014) (67). Control DARTs were sim-
ilarly constructed by replacing either the HIV or CD3 specificity with 
an irrelevant specificity from an anti-fluorescein mAb (4420) (68) or 
anti-RSV mAb (palivizumab) (69). DART-encoding sequences were 
cloned into CET1019AD UCOE vectors (EMD Millipore) and trans-
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plated at 5 × 104 cells per well in 96-well plates with 100 ng/ml of the 
indicated DART. Cells were cultured in 0.2 ml of cIMDM media supple-
mented with 10% FBS, 1% Penicillin/Streptomycin, and 5 U/ml IL-2 for 
7 days, and then stained with the following antibodies: HLA-DR-PerCP 
(clone L243), CD25-PE (clone M-A251), CD8-FITC (clone HIT8a), 
CD8-PE (clone HIT8a), CD4-FITC (clone RPA-T4), Annexin V-PE, and 
7-AAD (all BD Biosciences).
Redirected T cell viral clearance assay. CD8+ T cells were isolated 
from PBMCs by positive selection (EasySep human CD8+ Selection 
Kit, StemCell Technologies Inc.). CD8-depleted PBMCs were first 
activated with 2 μg/ml of PHA (Remel and Lenexa, Kansas, USA) 
and 60 U/ml of IL-2, and then infected by spinoculation at 1,200 × g 
for 90 minutes with either JR-CSF or AR virus at an MOI of 0.01 as 
previously described (49). AR virus was obtained from pooled super-
natants of replicate wells from outgrowth assays of resting CD4+ 
T cells for each patient performed as previously described (73). 
Fifty-thousand (5 × 104) targets/well were cocultured with CD8+ T 
cells in triplicate at the indicated E/T ratio in the absence or presence 
of 100 ng/ml of DART in 0.2 m of cIMDM media supplemented with 
10% FBS, 1% Penicillin/Streptomycin, and 5 U/ml IL-2 . For experi-
ments performed in the presence of ARVs, 24 hours after spinocula-
tion cells were washed and 1 μM of raltegravir and 4 μM of abacavir 
were added, and then DARTs and CD8+ T cells were added to cul-
tures. Supernatant was assayed on day 7 by p24 ELISA (ABL). Results 
are calculated as the log fold reduction (log of [p24 levels of infected 
target cells divided by p24 levels of the test condition]).
LCA. We assessed the reduction of virus recovery from CD4+- 
infected cells by a standard quantitative viral outgrowth assay using 
the resting CD4+ T cells of aviremic, ART-treated patients, fol-
lowing the addition of antiviral effector cells and/or molecules as 
previously described (49). In this case, we used the LCA to model 
the ability of DARTs to clear virus emerging from the latent reser-
voir under clinically and pharmacologically relevant conditions. 
Resting CD4+ T cells were isolated from a leukapheresis product as 
previously described (73) and either exposed to PHA (4 μg/ml) and 
IL-2 (60 U/ml) for 24 hours or VOR (335 nM, 6 hours) (Merck), and 
plated at 0.5 to 1 × 106 cells/well in 12–36 replicate wells, depending 
on the size of the reservoir. The VOR was then washed off and CD8+ 
T cells added at an E/T of 1:10, along with 100 ng/ml of the indi-
cated DART. Cells were cocultured for 24 hours (unless specified 
otherwise) following which the DART proteins were washed off and 
allogeneic CD8-depleted PBMCs from an HIV-1 seronegative donor 
were added to amplify residual virus. Supernatant was assayed for 
the presence of p24 antigen on day 15 for each well. Results are cal-
culated as percent viral recovery ([number of positive wells/total 
number plated] × 100), normalized to a control in which no CD8+ 
T cells are added.
Patient population. Leukapheresis samples were obtained from 
HIV seronegative donors or HIV-infected donors with undetectable 
plasma viremia (<50 copies/ml) on stable ART for at least 6 months, as 
indicated. Written informed consent was obtained from each patient, 
and the study was approved by the Duke and UNC Biomedical Institu-
tional Review Boards.
Statistics. Statistical comparisons between groups were analyzed 
using the Dunnett’s test for multiple comparisons using GraphPad 
Prism Software; P values <0.05, calculated with Dunnett correction 
for multiple comparisons, were considered significant.
at varying E/T ratios as indicated, and incubated at 37°C, 5% CO2 
overnight. Cytotoxicity was measured by LDH release (CytoTox 96 
Non-Radioactive Cytotoxicity Assay, Promega) as described pre-
viously (32). With the Jurkat-522 F/Y GF cell line, cytotoxicity was 
also measured by luminescence using Luciferase-Glo substrate 
(Promega). Specific lysis was calculated from luminiscence counts 
(RLU): cytotoxicity (%) = 100 × (1-[RLU of Sample/RLU of Con-
trol]), where control equals the average RLU of target cells incu-
bated with effector cells in the absence of DART. Data were fit to a 
sigmoidal dose-response function to obtain EC50 and percent max-
imum specific lysis values. T cell activation was measured by FACS 
analysis after cells in the assay plate were labeled with CD8-FITC, 
CD4-APC, and CD25-PE antibodies (BD Biosciences), followed by 
cell collection by FACS Calibur flow cytometer equipped with acqui-
sition software CellQuest Pro version 5.2.1 (BD Biosciences). Data 
analysis was performed using FlowJo software (Tree Star Inc.).
Redirected T cell cytotoxicity assay against HIV-1 IMC–infected 
CD4+ cells. Cryopreserved resting PBMC from normal healthy HIV-1 
seronegative donors were activated for 72 hours with anti–human 
CD3 (clone OKT3; eBioscience) and anti–human CD28 (clone 
CD28.2; BD Biosciences). Subsequently, a CD4+ enriched cell pop-
ulation (purity > 92.3%; average ± SD 95.73% ± 2.6%) was obtained 
by depletion of CD8+ T cells using magnetic beads (Miltenyi Biotec), 
spinoculated in the presence of the luciferase-expressing IMC- 
representing HIV-1 subtype AE (CM235), B (BaL), or C (1086.C) and 
cultured for 72 hours. CD4+-infected target cells were incubated with 
resting CD8+ effector cells (isolated by negative selection from autol-
ogous PBMC, CD8+ T cell Isolation Kit, Miltenyi Biotec) at 33:1, 11:1, 
3:1, and 0:1 E/T ratios in the absence or presence of DARTs for 6–48 
hours at concentrations ranging from 0.0001–1,000 ng/ml. Unin-
fected and infected target cells alone were included as additional 
controls. Each condition was tested in duplicate. After incubation, 
ViviRen Live Cell Substrate (Promega) was added and RLU was 
measured on a luminometer; %SL of target cells was determined as 
described previously (58).
T cell degranulation (CD107) assay. As described for the cytotox-
icity assay with HIV-1 IMC–infected cells as targets, activated CD4+ 
cells infected with HIV-1 BaL IMC were plated with resting CD8+ 
effector cells at a 33:1 E/T ratio in the absence or presence of 1 ng/ml 
DARTs and incubated for 6 hours. For the CD4+ T cell degranu-
lation, activated CD4+ T cells were either infected with JR-CSF 
and labeled with the viability (NFL1) and target-specific (TFL4) 
markers routinely utilized in our ADCC assay (71) or added to tar-
gets as effectors at a 10:1 ratio prior to addition of DARTs. Each 
condition was tested in duplicate. CD107 PE-Cy5 (clone H4A3; 
eBioscience) was titered and added during the last 6 hours of the 
incubation, along with Monensin solution (BD Biosciences) (72). 
A panel of antibodies consisting of LIVE/DEAD Aqua stain, anti–
CD3 APC-H7 (clone SK7; BD Biosciences), anti–CD4 BV605 (clone 
OKT4; BioLegend), and anti–CD8 BV650 (clone RPA-T8; BioLeg-
end) was used to detect CD107+ CD8+ T cells. After washing and 
fixation, samples were acquired on a custom-made LSRII (BD Bio-
science) within the next 24 hours. A minimum of 300,000 total 
viable events was acquired for each test. The analysis of the data 
was performed using the Flow-Jo software (Tree Star Inc.).
T cell viability and activation assays. CD8+ T cells and CD8-depleted 
PBMCs obtained from HIV-infected, ART-suppressed patients were 
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